Rimonabant Sanofi-Synthélabo.
Rimonabant, an antagonist of central cannabinoid type 1 (CB1) receptors, is being developed by Sanofi-Synthélabo for the potential treatment of obesity and as a potential smoking cessation agent. Phase III trials were initiated for obesity in August 2001 and were ongoing in September 2003. By September 2002, the compound had entered phase III trials for smoking cessation, and these trials were ongoing in September 2003.
Fernandez
Jose R
JR
University of Alabama at Birmingham, Department of Nutrition Sciences, Ryals Public Health Building, 1665 University Blvd, Birmingham, AL 35294-0022, USA.
Allison
David B
DB
D000818:Animals; D019440:Anti-Obesity Agents / Q000138:chemical synthesis / Q000737:chemistry / Q000493:pharmacokinetics; D014150:Antipsychotic Agents / Q000138:chemical synthesis / Q000737:chemistry / Q000493:pharmacokinetics; D001067:Appetite Depressants / Q000138:chemical synthesis / Q000737:chemistry / Q000493:pharmacokinetics; D002986:Clinical Trials as Topic; D006801:Humans; D009765:Obesity / Q000188:drug therapy; D010880:Piperidines / Q000138:chemical synthesis / Q000737:chemistry* / Q000493:pharmacokinetics; D026902:Potassium Channel Blockers / Q000138:chemical synthesis / Q000737:chemistry / Q000493:pharmacokinetics; D011720:Pyrazoles / Q000138:chemical synthesis / Q000737:chemistry* / Q000493:pharmacokinetics; D043884:Receptor, Cannabinoid, CB1 / Q000037:antagonists & inhibitors*; D000077285:Rimonabant; D016540:Smoking Cessation; D013329:Structure-Activity Relationship
D019440:Anti-Obesity Agents; D014150:Antipsychotic Agents; D001067:Appetite Depressants; D010880:Piperidines; D026902:Potassium Channel Blockers; D011720:Pyrazoles; D043884:Receptor, Cannabinoid, CB1; D000077285:Rimonabant